Flotetuzumab及其他T细胞免疫疗法上调急性髓系白血病细胞MHC II类分子表达
异基因造血干细胞移植后AML复发与MHC-II表达下调相关。研究显示,靶向CD123的flotetuzumab(FLZ)及靶向CD123、CD33或CD371的CAR-T细胞可在体外上调MHC-II表达,FLZ亦可在患者来源异种移植模型及临床试验中复发/难治AML患者中上调MHC-II,且该上调由IFN-γ介导。
要点
- FLZ及靶向CD123、CD33、CD371的CAR-T细胞在体外上调AML细胞MHC-II表达
- FLZ在患者来源异种移植模型及临床试验复发/难治AML患者中上调MHC-II表达
- FLZ诱导的MHC-II上调由IFN-γ介导
核心结论
- 靶向复发AML的T细胞免疫疗法可通过MHC非依赖机制及IFN-γ局部释放上调MHC-II的MHC依赖机制杀伤AML。
研究设计与样本
- 体外研究:使用MHC-II中等表达的THP-1 AML细胞系及4例HCT后复发且MHC-II低表达的原发AML样本。
- 体内研究:患者来源异种移植模型及临床试验中接受FLZ治疗的复发或难治AML患者。
主要发现
- FLZ(CD123×CD3双特异性DART分子)及靶向CD123、CD33或CD371的CAR-T细胞在体外上调THP-1细胞系及4例原发AML样本的MHC-II表面表达。
- FLZ在患者来源异种移植模型及临床试验中复发或难治AML患者中上调MHC-II表达。
- FLZ诱导的MHC-II上调由IFN-γ介导。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) relapse is one of the most common and significant adverse events following allogeneic hematopoietic cell transplantation (HCT). Downregulation of major histocompatibility class II (MHC-II) surface expression on AML blasts may represent a mechanism of escape from the graft-versus-malignancy effect and facilitate relapse. We hypothesized that T-cell immunotherapies targeting AML antigens would upregulate MHC-II surface expression via localized release of interferon gamma (IFN-γ), a protein known to upregulate MHC-II expression via JAK-STAT signaling. We demonstrate that flotetuzumab (FLZ), a CD123 × CD3 bispecific DART molecule, and chimeric antigen receptor expressing T cells targeting CD123, CD33, or CD371 upregulate MHC-II surface expression in vitro on a THP-1 AML cell line with intermediate MHC-II expression and 4 primary AML samples from patients relapsing after HCT with low MHC-II expression. We additionally show that FLZ upregulates MHC-II expression in a patient-derived xenograft model and in patients with relapsed or refractory AML who were treated with FLZ in a clinical trial. Finally, we report that FLZ-induced MHC-II upregulation is mediated by IFN-γ. In conclusion, we provide evidence that T-cell immunotherapies targeting relapsed AML can kill AML via both MHC-independent mechanisms and by an MHC-dependent mechanism through local release of IFN-γ and subsequent upregulation of MHC-II expression.
引用
- Rimando JC, Chendamarai E, Rettig MP, et al. Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells. Blood. 2023. PMID: 36563336. doi:10.1182/blood.2022017795
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。